The global non-alcoholic steatohepatitis (NASH) market was worth $1,379 million in 2018, and is projected to reach $22,678 million by 2026, growing at a CAGR of 58.7% from 2019 to 2026.
Non-alcoholic steatohepatitis (NASH) market is projected to exhibit double digit growth during the forecast period majorly due to growth in demand for ideal NASH therapeutics, surge in the prevalence of NASH, and expected launch of pipeline drugs during the forecast period. In addition, surge in prevalence of diabetes & obesity and improvement in awareness of NASH in developing region is projected to supplement the market growth during the forecast period. However, poor diagnosis of the disease and lack of ideal diagnostic techniques are projected to limit the market growth.
Segmentation
The global non-alcoholic steatohepatitis (NASH) market is segmented based on drug type, sales channel, and region. Based on drug type, the market is divided as vitamin E & pioglitazone, ocaliva, elafibranor, and selonsertib & cenicriviroc. According to sales channel, the market is classified into hospital pharmacy, online provider, and retail pharmacy. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Segment Review
At present, there is no FDA-approved drug to treat NASH. Lifestyle interventions are the first-line approach to manage patients with NASH; and then vitamin E & pioglitazone are recommended as first line drugs. Based on drug type, non-alcoholic steatohepatitis (NASH) market is segmented as vitamin E & pioglitazone, obeticholic Acid (OCA), elafibranor, and selonsertib & cenicriviroc. At present, vitamin E & pioglitazone segment dominates the non-alcoholic steatohepatitis (NASH) market, due to efficacy. On the other hand, elafibranor and selonsertib & cenicriviroc segments are expected to exhibit significant growth in the future, majorly due to its effectiveness in severely affected NASH patients.
According to sales channel, the global non-alcoholic steatohepatitis (NASH) market is categorized into hospital pharmacy, online provider, and retail pharmacy. At present, the retail pharmacy segment is the major revenue contributor, and is estimated to remain dominant during the forecast period due to the strong presence of drug stores & retail pharmacies around the world. On the other side, the online provider segment is anticipated to exhibit the fastest market growth due to rise in awareness of online pharmacies and increase in preference for online purchase over the traditional methods.
Elafibranor is projected to be one of the fastest growing drugs of the NASH market. The segment is projected to grow at a CAGR of 55.4% in the forecast period. The drug which is an oral treatment is GENFIT’s lead pipeline product. It has been positioned as a first-in-class drug to treat NASH. The drug is currently being evaluated in the clinical Phase 3 study RESOLVE-IT.
North America is expected to be a key revenue generating region in the forecast period. The market is projected to grow at a CAGR of 53% in the forecast period. Increasing incidence of disease in the region has created a growth opportunity for the drug makers. Manufacturers have been focusing on bringing out new drugs. For instance: Recently in November 2018, Gilead Sciences, Inc. unveiled that its drug Selonsertib which is a dual anti-apoptotic and anti-inflammatory drug is currently undergoing Phase-3 trials for NASH compensated cirrhosis and NASH fibrosis.
The key players profiled in the non-alcoholic steatohepatitis (NASH) market report include Allergan plc. (Tobira Therapeutics), Cadila Healthcare Limited, Conatus Pharmaceuticals Inc., Galmed Pharmaceuticals Ltd, Gemphire Therapeutics Inc., Genfit SA, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Novartis International AG, and Shire Plc.
Segmentation:
By Drug Type
By Sales Channel
By Region
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.1.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets, 2021
3.2.2. Top player positioning
3.3. Top winning strategies
3.4. MARKET DYNAMICS
3.4.1. Drivers
3.4.1.1. Upsurge in NASH-affected population
3.4.1.2. Rise in prevalence of diabetes & obesity
3.4.1.3. Surge in healthcare expenditures worldwide
3.4.2. Restraints
3.4.2.1. Insufficient diagnostic technologies for NASH
3.4.2.2. Poor demand in the underdeveloped countries
3.4.3. Opportunities
3.4.3.1. Strong presence of pipeline drugs
3.4.3.2. Unmet needs for NASH therapeutics
3.4.3.3. Growth opportunities in the emerging markets
3.4.4. Impact analyses
3.5. Pipeline analyses
CHAPTER 4: NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Vitamin E & pioglitazone
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.3. Obeticholic acid
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.4. Elafibranor
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.5. Selonsertib & cenicriviroc
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
CHAPTER 5: NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY SALES CHANNEL
5.1. Overview
5.1.1. Market size and forecast
5.2. Hospital pharmacy
5.2.1. Market size and forecast, by region
5.3. Online providers
5.3.1. Market size and forecast, by region
5.4. Retail pharmacy
5.4.1. Market size and forecast, by region
CHAPTER 6: NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. Market size and forecast, by country
6.2.2.1. U.S. market size and forecast
6.2.2.2. Canada market size and forecast
6.2.2.3. Mexico market size and forecast
6.2.3. North America nonalcoholic steatohepatitis (NASH) market, by drug type
6.2.4. North America nonalcoholic steatohepatitis (NASH) market, by sales channel
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Market size and forecast, by country
6.3.2.1. Germany market size and forecast
6.3.2.2. France market size and forecast
6.3.2.3. UK market size and forecast
6.3.2.4. Italy market size and forecast
6.3.2.5. Spain market size and forecast
6.3.2.6. Rest of Europe market size and forecast
6.3.3. Europe nonalcoholic steatohepatitis (NASH) market, by drug type
6.3.4. Europe nonalcoholic steatohepatitis (NASH) market, by sales channel
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Market size and forecast, by country
6.4.2.1. Japan market size and forecast
6.4.2.2. China market size and forecast
6.4.2.3. Australia market size and forecast
6.4.2.4. India market size and forecast
6.4.2.5. South Korea market size and forecast
6.4.2.6. Rest of Asia-Pacific market size and forecast
6.4.3. Asia-Pacific nonalcoholic steatohepatitis (NASH) market, by drug type
6.4.4. Asia-Pacific nonalcoholic steatohepatitis (NASH) market, by sales channel
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. Market size and forecast, by country
6.5.2.1. Brazil market size and forecast
6.5.2.2. Saudi Arabia market size and forecast
6.5.2.3. South Africa market size and forecast
6.5.2.4. Rest of LAMEA market size and forecast
6.5.3. LAMEA nonalcoholic steatohepatitis (NASH) market, by drug type
6.5.4. LAMEA nonalcoholic steatohepatitis (NASH) market, by sales channel
CHAPTER 7: COMPANY PROFILES
7.1. Allergan Plc (Tobira Therapeutics Inc.)
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. Cadila Healthcare Ltd.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Product portfolio
7.2.4. Business performance
7.3. Conatus Pharmaceuticals, Inc.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments
7.4. Galmed Pharmaceuticals Ltd.
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. Gemphire Therapeutics Inc.
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Key strategic moves and developments
7.6. Genfit SA
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.6.6. Key strategic moves and developments
7.7. Gilead Sciences, Inc.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments
7.8. Intercept Pharmaceuticals, Inc.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Novartis International AG
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.10. Shire plc
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY DRUG TYPE, 2017-2026 ($MILLION)
TABLE 02. NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET FOR VITAMIN E & PIOGLITAZONE, BY REGION, 2017-2026 ($MILLION)
TABLE 03. NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET FOR OBETICHOLIC ACID, BY REGION, 2017-2026 ($MILLION)
TABLE 04. NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET FOR ELAFIBRANOR, BY REGION, 2017-2026 ($MILLION)
TABLE 05. NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET FOR SELONSERTIB & CENICRIVIROC, BY REGION, 2017-2026 ($MILLION)
TABLE 06. GLOBAL NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY SALES CHANNEL, 2017-2026 ($MILLION)
TABLE 07. PHARMACY NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET FOR HOSPITAL, BY REGION, 2017-2026 ($MILLION)
TABLE 08. NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET FOR ONLINE PROVIDERS, BY REGION, 2017-2026 ($MILLION)
TABLE 09. NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET FOR RETAIL PHARMACY, BY REGION, 2017-2026 ($MILLION)
TABLE 10. NONALCOHOLIC STEATOHEPATITIS (NASH) REVENUE, BY REGION, 2017-2026 ($MILLION)
TABLE 11. NORTH AMERICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY COUNTRY, 2017-2026 ($MILLION)
TABLE 12. NORTH AMERICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY DRUG TYPE, 2017-2026 ($MILLION)
TABLE 13. NORTH AMERICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY SALES CHANNEL, 2017-2026 ($MILLION)
TABLE 14. EUROPE NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY COUNTRY, 2017-2026 ($MILLION)
TABLE 15. EUROPE NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY DRUG TYPE, 2017-2026 ($MILLION)
TABLE 16. EUROPE NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY SALES CHANNEL, 2017-2026 ($MILLION)
TABLE 17. ASIA-PACIFIC NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY COUNTRY, 2017-2026 ($MILLION)
TABLE 18. ASIA-PACIFIC NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY DRUG TYPE, 2017-2026 ($MILLION)
TABLE 19. ASIA-PACIFIC NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY SALES CHANNEL, 2017-2026 ($MILLION)
TABLE 20. LAMEA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY COUNTRY, 2017-2026 ($MILLION)
TABLE 21. LAMEA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY DRUG TYPE, 2017-2026 ($MILLION)
TABLE 22. LAMEA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, BY SALES CHANNEL, 2017-2026 ($MILLION)
TABLE 23. ALLERGAN: COMPANY SNAPSHOT
TABLE 24. ALLERGAN: OPERATING SEGMENTS
TABLE 25. ALLERGAN: PRODUCT PORTFOLIO
TABLE 26. ZYDUS CADILA: COMPANY SNAPSHOT
TABLE 27. ZYDUS CADILA: PRODUCT PORTFOLIO
TABLE 28. CONATUS: COMPANY SNAPSHOT
TABLE 29. CONATUS: PRODUCT PORTFOLIO
TABLE 30. GALMED: COMPANY SNAPSHOT
TABLE 31. GALMED: PRODUCT PORTFOLIO
TABLE 32. GEMPHIRE: COMPANY SNAPSHOT
TABLE 33. GEMPHIRE: PRODUCT PORTFOLIO
TABLE 34. GENFIT: COMPANY SNAPSHOT
TABLE 35. GENFIT: PRODUCT PORTFOLIO
TABLE 36. GILEAD: COMPANY SNAPSHOT
TABLE 37. GILEAD: PRODUCT PORTFOLIO
TABLE 38. INTERCEPT: COMPANY SNAPSHOT
TABLE 39. INTERCEPT: PRODUCT PORTFOLIO
TABLE 40. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 41. NOVARTIS: OPERATING SEGMENTS
TABLE 42. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 43. SHIRE: COMPANY SNAPSHOT
TABLE 44. SHIRE: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP PLAYER POSITIONING
FIGURE 04. TOP WINNING STRATEGIES, BY YEAR, 2014–2018*
FIGURE 05. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2014–2018* (%)
FIGURE 06. TOP WINNING STRATEGIES, BY COMPANY, 2014–2018*
FIGURE 07. IMPACT ANALYSES
FIGURE 08. NONALCOHOLIC STEATOHEPATITIS (NASH) PIPELINE (POTENTIAL PHASE II AND III DRUGS)
FIGURE 09. U.S. NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2026 ($MILLION)
FIGURE 10. CANADA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2026 ($MILLION)
FIGURE 11. MEXICO NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2026 ($MILLION)
FIGURE 12. GERMANY NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2026 ($MILLION)
FIGURE 13. FRANCE NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2026 ($MILLION)
FIGURE 14. UK NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2026 ($MILLION)
FIGURE 15. ITALY NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2026 ($MILLION)
FIGURE 16. SPAIN NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2026 ($MILLION)
FIGURE 17. REST OF EUROPE NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2026 ($MILLION)
FIGURE 18. JAPAN NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2026 ($MILLION)
FIGURE 19. CHINA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2026 ($MILLION)
FIGURE 20. AUSTRALIA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2026 ($MILLION)
FIGURE 21. INDIA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2026 ($MILLION)
FIGURE 22. SOUTH KOREA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2026 ($MILLION)
FIGURE 23. REST OF ASIA-PACIFIC NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2026 ($MILLION)
FIGURE 24. BRAZIL NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2026 ($MILLION)
FIGURE 25. SAUDI ARABIA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2026 ($MILLION)
FIGURE 26. SOUTH AFRICA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2026 ($MILLION)
FIGURE 27. REST OF LAMEA NONALCOHOLIC STEATOHEPATITIS (NASH) MARKET, 2017-2026 ($MILLION)
FIGURE 28. ALLERGAN: NET SALES, 2015-2017 ($MILLION)
FIGURE 29. ALLERGAN: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 30. ZYDUS CADILA: NET SALES, 2015-2017 ($MILLION)
FIGURE 31. ZYDUS CADILA: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 32. CONATUS: NET SALES, 2016–2017 ($MILLION)
FIGURE 33. GALMED: NET SALES, 2016–2017 ($MILLION)
FIGURE 34. GENFIT: NET SALES, 2015-2017 ($MILLION)
FIGURE 35. GILEAD: NET SALES, 2015-2017 ($MILLION)
FIGURE 36. GILEAD: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 37. INTERCEPT: NET SALES, 2015-2017 ($MILLION)
FIGURE 38. NOVARTIS: NET SALES, 2015-2017 ($MILLION)
FIGURE 39. NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 40. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 41. SHIRE: NET SALES, 2015-2017 ($MILLION)
FIGURE 42. SHIRE: REVENUE SHARE BY PRODUCT, 2017 (%)
FIGURE 43. SHIRE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers